Search

Your search keyword '"Chen, Shu-Chen"' showing total 281 results
Start Over Author "Chen, Shu-Chen"
281 results on '"Chen, Shu-Chen"'

22. Training Session and Detraining Duration Affect Lower Limb Muscle Strength Maintenance in Middle-Aged and Older Adults: A Systematic Review and Meta-Analysis.

Author

Yang, Yong, Chen, Shu-Chen, Chen, Chiao-Nan, Hsu, Chihw-Wen, Zhou, Wen-Sheng, and Chien, Kuei-Yu

Subjects
CARDIOVASCULAR fitness, RESISTANCE training, ONLINE information services, MEDICAL databases, META-analysis, TIME, SYSTEMATIC reviews, EXERCISE physiology, SPORTS, LEG, MUSCLE strength, EXERCISE intensity, MEDLINE, INFORMATION storage & retrieval systems, EXERCISE therapy, MIDDLE age, OLD age
Abstract

Muscle strength after detraining is still higher than the level before training, which is an important issue for middle-aged and older adults. The purpose of the present study was to examine the effects of detraining duration (DD), resistance training duration (RTD), and intensity on the maintenance of resistance training (RT) benefits after detraining in middle-aged and older adults. A systematic search yielded 15 randomized control trails (n = 383) eligible for inclusion. The results showed that RTD ≥ 24 weeks and DD ≥ RTD, the RT benefits were still significantly maintained even with medium and low intensity (standardized mean difference = 1.16, 95% confidence interval, CI [0.38, 1.94], p =.004). When RTD < 24 weeks and DD ≤ RTD, only the high-intensity groups maintained the RT benefits (DD, 4–6 weeks: standardized mean difference = 0.71, 95% CI [0.34, 1.08], p =.0002; DD 8–16 weeks: standardized mean difference = 1.35, 95% CI [0.66, 2.04], p =.0001). However, when DD > RTD, the RT benefits were not maintained even with high intensity. In summary, when RTD was less than 24 weeks, RTD > DD was an important factor in maintaining muscle strength. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

25. Effects of a ground-glass opacity component on the recurrence and survival of pathological stage IA3 lung adenocarcinoma: a multi-institutional retrospective study

Author

Shao-Jun, Xu, Chen, Rui-Qin, Jia-Hua, Tu, You, Cheng-Xiong, Chen, Chao, Zhang, Zhi-Fan, Divisi, Duilio, Migliore, Marcello, Bongiolatti, Stefano, Durand, Marion, Sato, Masaaki, Kuroda, Hiroaki, Yang, Chao-Fu, Shao-Bin, Yu, and Chen, Shu-Chen

Subjects
ground-glass opacity component (GGO component), Pathological stage IA3 lung adenocarcinoma, prognosis
Published
2023

32. Inhibition of lncRNA PART1 Chemosensitizes Wild Type but Not KRAS Mutant NSCLC Cells

Author

Chen, Shu-Chen, Diao, Yu-Zhu, Zhao, Zi-Han, and Li, Xiao-Ling

Subjects
PART1, chemosensitivity, erlotinib, lncRNA, Cancer Management and Research, KRAS, neoplasms, non-small cell lung cancer, respiratory tract diseases, Original Research
Abstract

Shu-Chen Chen,1 Yu-Zhu Diao,1 Zi-Han Zhao,2 Xiao-Ling Li1 1Medical Oncology Department of Thoracic Cancer 1, Cancer Hospital of China Medical University, Liaoning Cancer Hospital, Shenyang, Liaoning 110042, People’s Republic of China; 2The Second Clinical College of Dalian Medical University, Dalian, Liaoning 116044, People’s Republic of ChinaCorrespondence: Xiao-Ling LiMedical Oncology Department of Thoracic Cancer 1, Cancer Hospital of China Medical University, Liaoning Cancer Hospital, No. 44, Xiaoheyan Road, Dadong District, Shenyang, Liaoning 110042, People’s Republic of ChinaTel/Fax +86-24-31916361Email lixiaoling_med@163.comBackground: Lung cancer has the highest incidence among solid tumors in men and is the third most common cancer in women. Despite improved understanding of genomic and mutational landscape in non-small cell lung cancer (NSCLC), the five-year survival in these patients has remained stagnant at a dismal 15%. The first line of treatment commonly adapted for NSCLC patients with somatic mutation in EGFR is tyrosine kinase inhibitor gefitinib or erlotinib. EGFR mutant cells seem to be intrinsically sensitive to tyrosine kinase inhibitors; however, the remaining 20– 30% patients are resistant to tyrosine kinase inhibitor.Materials and Methods: Here we show, using in vitro normal and NSCLS cell lines, that the lncRNA Prostate androgen-regulated transcript 1 (PART1) is expressed at higher levels in NSCLC cells compared to normal lung epithelial cell line, corroborating two earlier studies.Results: We additionally show that these cells are resistant to erlotinib which is reversed in some, but not all, cell lines following suppression of PART1 expression. The differential response to erlotinib following siRNA-mediated knockdown of PART1 was found to be related to the mutational status of KRAS. Only in cells with wild-type KRAS suppression of PART1 sensitized them to erlotinib. Knockdown of mutant KRAS did not sensitize those cell lines to erlotinib. But knockdown of mutant KRAS along with suppression of PART1 sensitized the cells to treatment with erlotinib. The results from the study reveal a yet undefined and important role of lncRNA PART1 in defining sensitivity to erlotinib. This action is mediated by mutation status of KRAS.Conclusion: Even though preliminary, our results indicate PART1 might be a potential candidate for targeted therapy or used as a predictor of chemosensitivity in patients with NSCLC.Keywords: lncRNA, PART1, KRAS, non-small cell lung cancer, chemosensitivity, erlotinib

Published
2020

34. Comparative effectiveness of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers in patients with type 2 diabetes and retinopathy

Author

Shih, Chia-Jen, Chen, Hung-Ta, Kuo, Shu-Chen, Li, Szu-Yuan, Lai, Pi-Hsiang, Chen, Shu-Chen, Ou, Shuo-Ming, and Chen, Yung-Tai

Subjects
Angiotensin II receptor blockers -- Research -- Influence -- Comparative analysis, Diabetic retinopathy -- Care and treatment -- Comparative analysis -- Research -- Risk factors, ACE inhibitors -- Comparative analysis -- Research -- Influence, Type 2 diabetes -- Care and treatment -- Comparative analysis -- Research -- Complications and side effects, Health
Abstract

Background: Angiotensin-converting-enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are effective treatments for diabetic retinopathy, but randomized trials and meta-analyses comparing their effects on macrovascular complications have yielded conflicting results. We compared the effectiveness of these drugs in patients with pre-existing diabetic retinopathy in a large population-based cohort. Methods: We conducted a propensity score-matched cohort study using Taiwan's National Health Insurance Research Database. We included adult patients prescribed an ACE inhibitor or ARB within 90 days after diagnosis of diabetic retinopathy between 2000 and 2010. Primary outcomes were all-cause death and major adverse cardiovascular events (myocardial infarction, ischemic stroke or cardiovascular death). Secondary outcomes were hospital admissions with acute kidney injury or hyperkalemia. Results: We identified 11 246 patients receiving ACE inhibitors and 15 173 receiving ARBs, of whom 9769 patients in each group were matched successfully by propensity scores. In the intention-to-treat analyses, ARBs were similar to ACE inhibitors in risk of all-cause death (hazard ratio [HR] 0.94, 95% confidence interval [CI] 0.87-1.01) and major adverse cardiovascular events (HR 0.95, 95% CI 0.87-1.04), including myocardial infarction (HR 1.03, 95% CI 0.88-1.20), ischemic stroke (HR 0.94, 95% CI 0.85-1.04) and cardiovascular death (HR 1.01, 95% CI 0.88-1.16). They also did not differ from ACE inhibitors in risk of hospital admission with acute kidney injury (HR 1.01, 95% CI 0.91-1.13) and hospital admission with hyperkalemia (HR 1.01, 95% CI 0.86-1.18). Results were similar in as-treated analyses. Interpretation: Our study showed that ACE inhibitors were similar to ARBs in risk of all-cause death, major adverse cardiovascular events and adverse effects among patients with preexisting diabetic retinopathy., Diabetic retinopathy is among the most common microvascular complications in patients with type 2 diabetes and the leading cause of blindness in adults. The risk of incident macrovascular events is [...]

Published
2016
Full Text
View/download PDF

36. Textbook outcome after minimally invasive esophagectomy is an important prognostic indicator for predicting long-term oncological outcomes with locally advanced esophageal squamous cell carcinoma

Author

Xu, Shao-Jun, primary, Lin, Lan-Qin, additional, Chen, Chao, additional, Chen, Ting-Yu, additional, You, Cheng-Xiong, additional, Chen, Rui-Qin, additional, Deana, Cristian, additional, Wakefield, Connor J., additional, Shrager, Joseph B., additional, Molena, Daniela, additional, Yang, Chi-Fu Jeffrey, additional, Lin, Ji-Hong, additional, and Chen, Shu-Chen, additional

Published
2022
Full Text
View/download PDF

38. Accuracy of long-form data in the Taiwan cancer registry

Author

Cheng-Yi, Shiau, Lin, Hsiu-Ling, Lin, Mei-Man, Wang, Yi-Ping, Chen, Ming-Ling, Lin, Kuei-Chih, Shen, Yueh-Ying, Wu, Shu-Ching, Cheng, Shu-Chen, Chen, Pei-Lin, Lin, Yen-Chun, Wang, Su-Lan, Cheng, Chin-Ying, Chen, Chiao-Min, Chen, Shu-Chen, Cheng, Hui-Wen, Chiang, Liang-Yu, Kao, Wei-Ling, Su-Chien, Liao, Chang, Chia-Fen, Chen, Tsai-Chieh, Liau, Wei-Ling, Lin, Chia-Ling, Lee, Chia-Ling, Suen, Yueh-Yun, Wang, Chen-His, Lai, Win-Jieh, Huang, Tsai-Yun, Lin, Yu-Ru, Kao, Hui-Yu, Wei, Li-Hua, Huang, Ching-Chin, Kuo, Mei-Lin, Huang, Chiao-Pin, Chen, Shiau-Wei, Chiu, Li-Fang, Chang, Hui-Ting, Lin, Ling-Chu, Kao, Chia-Wen, Chiang, Chun-Ju, Lin, Li-Ju, Huang, Chiao-Wen, Lee, Wen-Chung, and Lee, Ming-Yang

Published
2021
Full Text
View/download PDF

39. Accuracy of long-form data in the Taiwan cancer registry

Author

Kao, Chia-Wen, primary, Chiang, Chun-Ju, additional, Lin, Li-Ju, additional, Huang, Chiao-Wen, additional, Lee, Wen-Chung, additional, Lee, Ming-Yang, additional, Cheng-Yi, Shiau, additional, Lin, Hsiu-Ling, additional, Lin, Mei-Man, additional, Wang, Yi-Ping, additional, Chen, Ming-Ling, additional, Lin, Kuei-Chih, additional, Shen, Yueh-Ying, additional, Wu, Shu-Ching, additional, Cheng, Shu-Chen, additional, Chen, Pei-Lin, additional, Lin, Yen-Chun, additional, Wang, Su-Lan, additional, Cheng, Chin-Ying, additional, Chen, Chiao-Min, additional, Chen, Shu-Chen, additional, Cheng, Hui-Wen, additional, Chiang, Liang-Yu, additional, Kao, Wei-Ling, additional, Su-Chien, Liao, additional, Chang, Chia-Fen, additional, Chen, Tsai-Chieh, additional, Liau, Wei-Ling, additional, Lin, Chia-Ling, additional, Lee, Chia-Ling, additional, Suen, Yueh-Yun, additional, Wang, Chen-His, additional, Lai, Win-Jieh, additional, Huang, Tsai-Yun, additional, Lin, Yu-Ru, additional, Kao, Hui-Yu, additional, Wei, Li-Hua, additional, Huang, Ching-Chin, additional, Kuo, Mei-Lin, additional, Huang, Chiao-Pin, additional, Chen, Shiau-Wei, additional, Chiu, Li-Fang, additional, Chang, Hui-Ting, additional, and Lin, Ling-Chu, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results